ImageneBio (IMA) Change in Accured Expenses (2020 - 2025)

ImageneBio has reported Change in Accured Expenses for 6 years, with the latest figure at -$6.8 million in Q3 2025.

• Quarterly Change in Accured Expenses fell 243.49% year-over-year to -$6.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$11.7 million (down 279.44% YoY) and the FY2024 annual result came in at -$2.5 million, up 67.57% from the prior year.
• Change in Accured Expenses eased to -$6.8 million in Q3 2025 per IMA's latest filing, from -$2.8 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.8 million in Q3 2024 and troughed at -$6.8 million in Q3 2025.
• A 5-year average of -$871631.6 and a median of -$1.5 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2021 and 2023: Change in Accured Expenses soared 9480.0% in 2021, then sank 301.37% in 2023.
• Over 5 years, Change in Accured Expenses stood at $1.7 million in 2021, then plunged by 134.57% to -$586000.0 in 2022, then tumbled by 301.37% to -$2.4 million in 2023, then rose by 25.47% to -$1.8 million in 2024, then sank by 289.39% to -$6.8 million in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$6.8 million, -$2.8 million, and -$306000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.